Life Sciences Voice Top Five Newsletter

January 22, 2025

Europe Approves Novo Nordisk’s Ozempic for Reducing Kidney Disease Risk

December 21, 2024

Subtle Medical Gets $33M Series C Funding, Appoints New CEO

June 4, 2026

Must Read

Top 10 AI Risks Every Pharmaceutical Executive Should Understand

September 10, 2026

The Rise of Autonomous Laboratories

September 10, 2026

Phase 3 of Ultragenyx fails to plot “significant expense reductions” using the Angelman test

September 10, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Phase 3 of Ultragenyx fails to plot “significant expense reductions” using the Angelman test

Following the cancelation of more phase 3 trials, Novo’s blockbuster aspirations for the CKD program decline

Ziihera Delivers Second Survival Win in Advanced HER2-Positive Stomach Cancer Trial

Novartis Reports Positive Phase 3 Results for Rhapsido in Relapsing Multiple Sclerosis

GSK Signs Deal With Hutchmed to Get Early-Stage KRAS-EGFR Cancer Asset

Roche’s Genentech Partners With DualityBio on ADCs Designed to Address Cancer Drug Resistance

Cureety Buys Out AI-Focused Oncology Firm Reimagine Care

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Top 10 AI Risks Every Pharmaceutical Executive Should Understand

The Rise of Autonomous Laboratories

How Synthetic Data Is Changing Clinical Research

Top 10 Technologies Improving Market Access in Pharma

Tag: Neurocrine

Neurocrine’s Depression Drug Encounters Surprising Phase II Failure

Editor Picks

Life Sciences Voice Top Five Newsletter

Europe Approves Novo Nordisk’s Ozempic for Reducing Kidney Disease Risk

Subtle Medical Gets $33M Series C Funding, Appoints New CEO

Must Read

Top 10 AI Risks Every Pharmaceutical Executive Should Understand

The Rise of Autonomous Laboratories

Phase 3 of Ultragenyx fails to plot “significant expense reductions” using the Angelman test

Hot Topics

About Us

Follow Us